Use of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Donepezil is a commonly used drug in older people that due to its procholinergic effects can provoke bradycardia and neurocardiogenic syncope. Donepezil is metabolized by the cytochrome P450 isozyme 3A4 (CYP3A4). Clarithromycin is a potent inhibitor of CYP3A4, and patients taking both of these drugs may be at increased risk of cardiac adverse events.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Drugs Aging

Title: Drugs & aging

Publisher: Springer Nature America, Inc

ISSN (Electronic): 1179-1969

ISSN (Print): 1170-229X

Publication date (Electronic): Mar 01 2012

Volume: 29

Issue: 3

Affiliations

[1 ] Faculty of Medicine, University of Toronto, Toronto, ON, Canada. j.hutson@utoronto.ca.

[2 ] Sunnybrook Health Sciences Centre, Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.

[3 ] Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.

[4 ] Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada.

[5 ] Department of Medicine, Queen's University, Kingston, ON, Canada.

[6 ] Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Article

Publisher Item ID: 10.2165/11599090-000000000-00000

DOI: 10.2165/11599090-000000000-00000

PubMed ID: 22372724

SO-VID: 37d48450-8c22-48e4-9e70-0e1093b94cf9

History

Data availability:

Comments

Comment on this article

scite_

Cited by 7

See all cited by